Renalytix to Present at H.C. Wainwright Conference

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, NY and SALT LAKE CITY, UT    September 8, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the Company's website at https://investors.renalytix.com beginning at 7:00 a.m. Eastern Time on September 12, 2022.

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis^TM for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit  www.renalytix.com .

For further information, please contact: